Adhansia XR

Question 1

Indication and Usage

Answer 1

Adhansia XR is a central nervous system (CNS) stimulant indicated for the treated of ADHD in patients 6 years and older

Question 2

Dosage

Answer 2

The recommended starting dose of Adhansia XR for patients 6 years of older is 25mg once daily

Question 3

Administration

Answer 3

Adhanisa XR may be taken whole or the capsule may be opened and the entire contents sprinkled onto a tablespoon of applesauce or yogurt. The entire mixture should be consumed immediately or within 10 minutes

Question 4

Dosage Form, Strengths, Colors

Answer 4

25 mg - Blue
35 mg - Orange
45 mg - Yellow
55 mg - Light Green
70 mg - Iron Gray
85 mg - White

Question 5

Adhansia XR is available in how many strengths?

Answer 5

6

Question 6

Contraindications

Answer 6

Adhansia XR is contradicted in patients:

1. With a known hypersensitivity to methylphenidate
2. Receiving concomitant treatment with monoamine oxidase inhibitors (MAOI) and also within 14 days following discontinuation of treatment with a MAOI

Question 7

T/F One capsule delivers both an immediate and an extended dose

Answer 7

True

Question 8

T/F Each capsule consists of identical multilayer beads

Answer 8

True

Question 9

T/F Each bead consists of multiple layers of drug and drug-release-controlling excipients

Answer 9

True

Question 10

The immediate-release layer contains approximately ___% of the methylphenidate dose, and the controlled-release layer contains approximately ____% of the methylphenidate dose

Answer 10

20%, 80%

Question 11

The immediate-release layer contains approximately ___% of the methylphenidate dose

Answer 11

20%

Question 12

The controlled-release layer contains approximately ____% of the methylphenidate dose

Answer 12

80%

Question 13

Patients Savings Card

Answer 13

Commercially insured patients may pay as little as $15
The Patients Savings Card allows eligible patients to fill their prescriptions for Adhansia XR, while at the sam time offering the office Tim to process a Prior Authorization if one is required

Question 14

Child Onset and Duration Study

Answer 14

Symptom Improvement
Primary Endpoint - 9 point difference in SKAMP-C scores which was statically significant when scores were averaged across all time points vs. placebo post dose
Secondary Endpoint - onset and duration which demonstrated statistically significant symptom improvement from hour 1 through hour 13 vs placebo

Question 15

Adolescent Study

Answer 15

Symptom Improvement
Adhansia XR provided symptom control with the patient population versus placebo
Significant improvements were demonstrated at doses of 45mg, 70mg, and with all doses pooled

Question 16

T/F You can substitute Adhansia XR on a mg-per-mg basis when switching from another methylphenidate

Answer 16

False (because of base comparisons and PK profile)